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Removal of metastatic neuroblastoma cells using magnetic 
immunobeads with newly produced antibodies were inves-
tigated. Magnetic immunobeads were M-450 (DYNAL) 
coated with purified sheep polyclonal IgG against all 
mouse IgG subclass. Two newly produced antibodies (5E9 
and 3C1) and other two antibodies were used. Four anti-
bodies were added to a mixture of the neuroblastoma cells 
stained with Hoechst 33342 with the human bone marrow 
cells. The magnetic immunobeads were added to the cell 
mixture. After incubation for 30 min at 4 °C , the magnetic 
beads reacted to the neuroblastoma cells were removed by 
using cobalt samarium magnets. The residual neuro-
blastoma cells were assayed under the fluorescence micros-
copy, and the clonogenic capacity of the bone marrow 
progenitor cells were measured by culturing in the soft agar 
assay. A ratio of neuroblastoma cells to normal bone 
marrow cells was 1:10 and a ratio of magnetic immuno-
beads to neuroblastoma cells was 100:1. A tumor cells 
depletion rate of 1.9-3.8 logs was achieved using the 
cocktail antibodies with 5E9, 3C1, NCC-LU-243 and 
NCC-LU-246 and second cycle treatment. In a clinical cell 
separation unit 2.81 log removal rate of tumor cells was 
obtained. Residual rate of human normal bone marrow 
cells after second cycle purging was 17.1%. Reduction in 
the clonogenic bone marrow progenitor cells was about 
10%. 
 This purging method in use the procedure with the 
magnetic immunobeads and neuroblastoma cell antibodies 
seems to offer advantage with respect to speed and sim-
plicity. By use of suitable antibodies, the immunomagnetic 
tumor cell depletion method is useful in autologous bone 
marrow transplantion of advanced neuroblastoma children 
with poor prognosis. Newly produced antibodies 5E9 and 
3C1 are of great use in the immunomagnetic tumor cell 
depletion procedure.
Introduction 
Several groups have reported autologous bone marrow 
transplantation (ABMT) for advanced cancer with poor 
prognosis after conventional therapy.'-" ABMT is of help in
preventing prolonged aplasia after chemotherapy and ra-
diotherapy. Since the bone marrow is frequently invasived 
by tumor cells in such cases, it is important to remove the 
metastatic malignant cells form the harvested bone marrow 
before transplantation. A number of techniques have been 
studied to deplete metastatic malignant cells from the 
harvested bone marrow for ABMT. In this study the 
magnetic immunobeads method was evaluated with newly 
produced monoclonal antibodies (3C I and 5E9) to neuro-
blastoma cells. Human neuroblastoma cell lines were seed 
into normal human bone marrow, incubated with mono-
clonal antibodies, and mixed with magnetic immunobeads. 
Tumor cells that attached to the magnetic beads were 
removed with cobalt magnets from the normal bone mar-
row (Fig. 1). The purging procedure was scaled up to the 
clinical use model. Removal rate of the tumor cells was 
achieved 1.9-3.8 logs. It was confirmed the newly pro-
duced antibodies did not affect normal bone marrow cells 
was observed.
Materials 
(1) Magnetic immunobeads: 
DYNABEADS M-450 (DYNAL) products are based on 
extremely uniform, superparamagnetic polystyrene beads 
with diameter 4.5 micron, a surface area of 3-5m2/g. A 20% 
Fe in the form of a maghemite (Fe2O3) containing core 
covered with a polymer is easily coated with antibodies or 
other selection molecules on the smooth surface. The beads 
coated with purified sheep polyclonal Ig against all mouse 
IgG subclasses were used in the study. 4 X 108 DYNA-
BEADS per ml is suspended in pH 7.4 PBS. 
(2) Neuroblastoma cell lines: 
Six neuroblastoma cell lines (1. GOTO 2. Nb/1N 3.SJ-
NCG 4.RT/LN S.IMR-32 6.ST-300) were prepared for this 
study. Cell lines were cultured in RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS). Cultures 
were diluted frequently to assure that cells were polif-
Fig. 1. Indirect procedure of magnetic immunobeads depletion. Mangetic immunobeads coated with sheep anti-mouse IgG are added to 
monoclonal antibodies selective for target neuroblastoma cells. Neuroblastoma cells attached to magnetic immunobeads can be removed 
with a magnet.
crating optimally. 
(3) Monoclonal antibodies: 
In this study four monoclonal antibodies were used (Table 
1). Antibodies NCC-LU-243 and NCC-LU-246 were estab-
lished in the laboratory of the NIHON-KAYAKU Co. Ltd. 
Each reactivities of the antibodies were human lung small 
cell carcinoma, and immunoglobulin subclass were IgG, 
and IgG,. Molecular weight of each antibodies were 145kd 
by SDS-PAGE. Other two monoclonal antibodies 5E9 and 
3C1 were newly produced in the National Children Medical 
Research Center in Tokyo. The 5E9 and 3C1 were an IgG,, 
and an IgG, mouse monoclonal antibody obtained by im-
munization with immature teratoma cell lines
Table 1. Characteristic of monoclonal antibodies
Name of antibody Subclass Reactivity 
     5E9 IgG, Anti-human immature teratoma 
     3C1 IgG2. Anti-human immature teratoma 
 NCC-LU-243 IgG2. Anti-human small cell lung cancer 
 NCC-LU-246 IgG, Anti-human small cell lung cancer
(4) Bone marrow: 
Bone marrow cells for this study were obtained from the 
patients undergoing bone marrow aspiration. No patients 
had bone marrow malignant involvement at smears. Mono-
nuclear cells (MNCs) were isolated on the Lymfoprep 
according to gradient centrifugation. MNCs were resus-
pended in RPMI 1640 medium with 20% FCS
Methods 
(1) Determination of Monoclonal antibodies binding to 
neuroblastome cell lines: 
Neuroblastoma cell lines were grown in RPMI 1640 with 
10% fetal calf serum at 37 °C . Cell lines were detached in 
TRY (-) 8mM-EDTA (+) -PBS for 30 min and suspended. 
The cells were cetrifugated and the pellet was resuspended 
to requlate 1 x 106/ml in PBS. We used the cells viability 
more than 70% with experiment of 5% trypan blue stain 
The suspended cells were washed twice with PBS. After 
the cells were pelleted by centrifugation, the wash solution 
was aspirated, and the pellets were resuspended with PBS. 
The monoclonal antibody was added to the cells in a final 
volume of lml in a tube. The tubes were incubated at 4 °C 
for 30min, washed twice with PBS, and added FITC. After 
incubated on 4 °C for 30min the cells was washed twice 
with PBS and then analyzed with the FCM (EPICS). The 
amount of each antibodies to pipette into the sample were 
64,ug, 32,ug, 16,ug, 8,ug, 4,ug, 2,ug, l ,ug, 0.5,ug, 0 25,ug, 
0.125,ug and 0 0625,ug. Control sample was added with 
non-specific antiboby 10B5.
(2) Evaluation of single antibody and cocktail antibodies 
binding to tumor cells: 
Good effect of cocktail antibodies to tumor cells have been 
reported.""'At the clinical treatment of the purging 
procedure the antibody have been used three or four anti-
bodies specific for the tumor cells. To determine in combi-
nation with cocktail of antibodies (5E9, 3C1, NCC-LU-243 
and NCC-LU-246) binding to tumor cells, we compared the 
individual antibody with the cocktail antibodies binding to 
tumor cells. 
(3) Analysis of residual tumor cells: 
Culture assays is not sufficient sensitive to detect residual 
malignant cells. In this report we use the stain method of 
the Hoechst 33342 described by Reynolds."' It can be 
detected up to 3-4 log depletion under microscopic analysis 
immediately and repeatedly. Tumor cell lines were incu-
bated for 90min at 37 °C with the vital DNA dye Hoechst 
33342 in the final density 20,aM. After washing the tumor 
cells with PBS three times, the cells were detached with 
5mM EDTA-Try (-) PBS. The tumor cells were seeded into 
bone marrow cells 5-10%. After purging procedure, resid-
ual viral tumor cells were counted under the fluorescence 
microscopy. Counterstaining the residual tumor cells with 
5% vital dye trypan blue limits the detection of viral tumor 
cells, because trypan blue penetrate into dead cells and 
quenches the DNA Hoechst 33342 stain.
(4) Determination of the volume of the magnetic immuno-
beads: 
To evaluate optimal tumor cell and magnetic immunobeads 
ratio, neuroblastoma cells prestained with Hoechst 33342 
in 1 X 106/ml per a tube were reacted with antibodies and 
then incubated on 4 °C for 30min. After washing twice with 
PBS, several numbers of magnetic beads were added to 
samples and incubated on 4°C for 30min. Tumor cells 
binding to magnetic beads were removed with a magnet 
and residual tumor cells were counted. 
(5) Reaction of antibodies to normal bone marrow: 
Antibodies showed non-specific reaction to normal bone 
marrow cells not only to neuroblatoma cell lines. Normal 
human bone marrow was prepared and incubated in RPMI 
1640 with 20% FCS for 1 day. Bone marrow was washed 
twice with PBS and added individual antibodies, cocktail 
antibodies, NKH 1, and CD45. And then FITC was added to 
the sample, incubated for 30min at 4 °C . After washing the 
sample with PBS, reactivity of antibodies to normal bone 
marrow cells were evaluated by the FCM. 
(6) Purging procedure (Fig. 2): 
Tumor cells prestained with Hoechst 33342 were seeded 
into the 1 X 10' bone marrow cells with 5-10% in a tube to 
I ml. The cell mixture was incubated with optimal volume 
of monoclonal antibodies at 4°C for 30min. The sample
Fig. 2. In vitro model procedure for removing neuroblastoma cells using monoclonal antibodies and magnetic immunobeads.
was then washed with PBS two times and resuspended with 
PBS to 3m1. And then magnetic immunobeads was added 
to the sample. The sample with the magnetic beads in a 
tube was gently rotated preventing precipitation for 30min 
at 4T. The tube with sample was fixed at a cobalt 
magnetic stand for 10min at 4C. The tumor cells binding 
to magnetic beads and free magnetic beads were retained. 
Supernatant was aspirated gentle to a new tube. A second 
purging procedure was performed with 30% volume of 
magnetic immunobeads. After first and second purging 
procedure, the supernatnat was stained with 5% trypan 
blue. Residual tumor cells stained with Hoechst 33342 and 
viable bone marrow cells were counted by a fluorescent 
microscope. 
(7) Cell separation unit for clinical use: 
The cell separation unit available from Dynal is shown in 
Fig. 3. The bag with bone marrow cells and beads were 
fixed on a cassette placed on the platform of rocking 
device. The cassette have a bank of cobalt samarium 
magnets giving the maximun and favorable magnetic field 
gradient to the blood bag. The platform with the fixed
blood bag can be changed stepwise decreasing or increas-
ing the magnetic field strength to change the distance of 
magnets. A tube of the blood bag is connected to a new 
blood bag via a pump and a magnetic trap. The magnetic 
trap of 150ml plastic bag collect free magnetic imrnuno-
beads from the blood bag with bone marrow and beads. 
 Bone marrow cells in a blood bag was incubated with a 
cocktail antibodies at 4 °C for 30min. After single washing 
with PBS, bone marrow cells diluted with RPMI 1640 
supplemented with 10% FCS were added with magnetic 
immunobeads. At 4 °C for 30min, the bag was incubated in 
gentle tilting. And the bag was fixed on the platform with 
tilting. A distance from the bag to magnet bank was de-
creasing stepwise, 3min being used at each of the different 
levels, giving 10%, 25%, 50% and 100% of the maximal 
field strength. The supernatant cell suspension of the blood 
bag is transferred to a new blood bag by means of a pump 
through a magnetic trap. A second cycle of purging is then 
carried out by adding the 30% of beads and repeating the 
separation procedure described above.
                                   Fig. 3. Cell separation unit for clinical use. 
1:200-400m1 Fenwall blood bags, 2:Rocking device, 3a:Platform supporting blood bag above bank of magnets, 3b:Enlarged cross section 
of 3a, 4:Removal iron plate with cobalt samarium magnets bar, 5:Handle for stepwise regulation of distance between platform and 
magnets, 6:Cobalt samarium magnets, 7:Peristaltic pump, 8a:Magnetic trap, 8b:Enlarged cross section of 8a.
(8) No harzard of antibodies to normal bone marrow: 
Untreated normal bone marrow cells and bone marrow 
cells after purging were cultured in soft agar (Methyl 
cellurose method)."," In untreated group using 5 x 105 
bone marrow cells/ml, containing 1% methyl cellurose, 
20% fetal calf serum and 10% PHA-LCM, were cultured in 
IOml dishes. Dishes were incubated for two weeks at 37 °C 
in a humidified 5% CO, atmosphere. The colony, numbers 
of cells over 40 cells, were counted by an inverted micro-
scope. The purging group treated the 5 X 105 bone marrow 
cells/ml with same volume of cocktail antibodies and 
magnetic immunobeads as described (6) purging proce-
dure. The colony (CFU-GM) was counted after two weeks.
Result 
(1) Determination of monoclonal antibodies binding to 
neuroblastoma cell lines: 
For valuation binding of each amount of antibodies, we 
used binding index." 
 Binding index = Mean fluorescence x % of cells posi-
tive/100. The mean fluorescence and percentage of cells 
positive were calculated by a FCM. Representative amount 
of four antibodies and binding index to neuroblastoma cell 
lines of individual antibody in this experiment were shown 
in Fig. 4. The binding profiles for 5E9, the binding index 
showed palteau more than 8,ug/ml for every tumor cell 
lines. Other three antibodies, 3C 1 > 8,u g/ml, NCC-LU-243
Fig. 4. Tirtation of antibodies 5E9, 3C1, NCC-LU-243 and NCC-LU-246 on the six human neuroblastoma cell lines (• ;GOTO, 
;SJ-HCG, A ;Nd-1N, O ;RT/LN, EI :IMR-32, A ;ST-300). Binding of antibody on cell lines was quantified by flow cytometry. B. I.: 
binding index. B. I. = Mean fluorescence x % of cells positive/100
> 4,ug/ml and NCC-LU-246 > 4,ug/ml, showed maximum 
reaction against tumor cells. In consequence the optimal 
concentration of antibodies for this study was decided that 
5E9 and 3C1 were l0,ug/ml, and NCC-LU-243 and NCC-
LU-246 were 4,u g/ml. 
(2) Comparison of individual antibodies and cocktail anti-
bodies binding to neuroblastoma cell lines: 
The effect of a mixture of four antibodies is shown in Fig. 
5. Specificity for each tumor cells of antibody 30 gave 
consistently higher fluorescence than other three anti-
bodies. 5E9, NCC-LU-243 and NCC-LU-246 had weak 
reaction to the tumor cell RT/LN, ST-300 and IMR-32. But 
when adding four antibodies, the binding index of a 
mixture antibodies was increased more 1.2-70 times than 
when only single antibody used in every cell lines. The 
results suggest that a cocktail of the four antibodies were 
suitable for the purpose of this purging procedure of neuro-
blastoma cells.
Fig. 6. Effect of increasing the magnetic immunobeads/tumor cell 
ratio on removal of neuroblastma cells from human bone marrow 
cells.
depletion and over 3-log elimination. In conclusion, it was 
suitable for purging procedure that the magnetic immuno-
beads/tumor cells ratio was 100. 
(4) Reaction of antibodies to normal bone marrow cells: 
Percentage of bone marrow positive rate and binding index 
(range x 100) of antibodies are shown in Fig. 7. MoAb
Fig. 5. Comparsion of the binding to six human neuroblastoma 
cell lines (GOTO, Nb/1M, RT/LN, ST-300, IMR-32 and SJ-NCG) 
of individual antibodies and a cocktail (5E9 + 3C1 + NCC-
LU-243 + NCC-LU-246).
(3) Magnetic immunobeads/tumor cells ratio: 
Effect of increasing the magnetic beads/tumor cells ratio on 
removal of neuroblastoma cells from bone marrow was 
shown in Fig. 6. The effect of increasing the ratio of beads 
to tumor cells was studied to establish the optimal concen-
tration of the magnetic immunobeads to be used. The 
sample was treated with cocktail antibodies of SE9, 3C1, 
NCC-LU-243 and NCC-LU-246. Viability of neuro-
blastoma cells was detected with 5% trypan blue staining 
exclusion and cells with viability over 70% were used. As 
increasing the amount of magnetic beads per tumor cells, 
residual tumor cells were decreased. Until the magnetic 
beads/tumor cells ratio reached 64-128, depletion of tumor 
cells depended on the magnetic beads. But 64-128 of 
beads/cells ratios were observed at highest tumor cell
Fig. 7. Comparsion of the non-specific binding to human bone 
marrow cells of each antibodies. Cocktail consists of four anti-
bodies 5E9, 3C1, NCC-LU-243 and NCC-LU-246.
NKH1 (IgM isotype) recognizes an antigen specifically 
expressed on natural killer cells in normal bone marrow. 
MoAb CD45 (IgM isotype) recognizes common antigen for 
panleukocytes. A cocktail consists of 5E9, 3C1, NCC-
LU-243 and NCC-LU-246. 3C I and a cocktail antibody 
showed a 20% positive reaction to normal bone marrow 
cells- But binding index of 3C1 and a cocktail assured to be 
the binding between tumor cells and antibodies was enor-
mously small in comparsion to the CD45. It is assumed that 
these antibodies have a minor impact on non specific 
removal of human bone marrow cells in this purging 
procedure. 
(5) Efficacy of tumor cells depletion in this experiment: 
Residual tumor cells after first and second treatment of 
purging procedure were shown in Fig. 8. Control samples 
were made by same purging procedure without cocktail 
antibodies or magnetic beads. IMB groups were treated 
with magnetic beads. In control groups after one and two 
purging procedures, tumor cells were decreased 0.5-1.0 log 
depletion by manipulation. IMB groups showed a small 
number of cells after treatment that result from mechanical 
damage to cells in addition to manipulated damage. In 
purging groups with MoAbs and beads first cycle treatment 
gave 3.0 log depletion of tumor cells in WIN, 2.9 log 
depletion in IMR-32 and 1.9 depletion in GOTO cell line. 
Second cycle treatment revealed additional 0.8 log deple-
tion in WIN and 0.2 log depletion in IMR-32, but in 
GOTO cells no more depletion was obtained. The effect of 
a second cycle treatment is evident in Nb/1N cell line and 
not so clearly in other two cell lines. In this second proce-
dure 30% of beads were used as in the first treatment. 
Increasing the beads in second treatment, the result of 
tumor depletion was not improved. In only one cell line the
second cycle treatment showed evident cell depletion, but 
two cycle treatment is of great value to decrease tumor 
cells from harvested bone marrow. 
(6) Efficacy of purging on a clinical cell separation unit: 
Bone marrow for this study was obtained form a patient of 
Rabdomyosarcoma at conditioned CR and stored in liquid 
nitrogen. Total volume of the bone marrow was 120ml and 
1.0 x 10' cells/ml. Cell viability was 30% so that the total 
viable cells were 3.6 X 1.08 in number. Tumor cells Nb/1N 
pre-stained with Hoechst 33342, density 1.0 X 10'/ml were 
seeded 10ml (1.0 X 108 cells) into the bone marrow cells. 
The ratio of tumor cells/viable bone marrow cells was 0.28. 
Total volume of the sample mixed with bone marrow and 
tumor cells was 130ml. Viable bone marrow cells in the 
reobtained sample were 1.26 X 108 which corresponded to 
35% of the initial cells. Viability of the residual bone 
marrow cell exceeded 90% by dye exclusion. Residual 
tumor cells counted by a fluorescent microscopy were 1.54 
X 105 and removal rate was 99.846% (removal of a 2.81 
log). This experiment unit resulted in a 2.81 log elimination 
of tumor cells. 
(7) Recovery of progenitor cells after purging: 
Fig. 9 showed the residual bone marrow cells rate after 1st 
and 2nd purging as compared with pre-purging. Normal 
bone marrow cells were removed through the process of 
purging tumor cells form the marrow, because some anti-
bodies adhere to the surface of the normal bone marrow 
cells. In the experiment with a tube and a clinical purging 
unit, the recovery bone marrow cells after two cycle of 
pruging varied from 17.1 to 35%. Bone marrow cells were 
mechanically damage by the purging procedure. However 
viability of bone marrow cells was 70-80%. 
 The toxicity of the CFU-GM was evaluated with culture 
assay. The result of the CFU-GM assay was shown in 
Table 2. CFU-GM numbers were 63.2 + 28.1 before prug-
Fig. 8. Residual tumor cells after one and two cycles of treatment 
of depletion of neuroblastoma cells. The number of residual tumor 
cells express log base. Control means purging without monoclonal 
antibodies and magnetic immunobeads, IMB with only magnetic 
immunobeads and MoAds with monoclonal antibodies and mag-
netic immunobeads. Columes, means of three determination; 
left:pre-purging, center:after first purging, right:after second purg-
ing.
Fig. 9. Residual rate of bone marrow cells. Control means only 
purging procedure without monoclonal antibodies and magnetic 
beads. IMB, treatment with magnetic beads with no antibodies. 
IMB + MoAbs means with both cocktail antibodies and mangetic 
beads. Each bar demonstrates the rate of residual bone marrow 
cells number after one or two cycle purging to pre-purging.
Table 2. Colony number of progenitor bone marrow cells at 
pre-purging and after two cycle purging treatment. Samples 
contained 5 x 105 bone marrow cells.
             CFU-GM 
pre-purging after two cycle of treatment 
63.2 ± 28.1 56.4 ± 30.5
ing and 56.4 ± 30.5 after two cycle of purging. Reduction 
in the clonogenic bone marrow progenitor cells was about 
10%. It was documented these antibodies did not affect 
progenitor cells of human.
Discussion 
Massive chemoradiotherapy for advanced neruoblastoma 
dose not significantly improved the prognosis. Autologus 
bone marrow transplantation (ABMT) for advanced neuro-
blastoma is now used to improve poor prognosis after 
conventional treatment. Bone marrow is generally har-
vested during clinical complete remission (CR), but the 
probability of the presence of metastasized tumor cells is 
great concern. A variety of method have been studied to 
remove tumor cells from involved bone marrow harvested 
for ABMT. Reisner (1983) reported a depletion model with 
soybean agglutinin."' Sarrinen et al. (1985) have shown 
killing the tumor cells using the monoclonal antibody of 
IgG3 isotype and human complement."' Fridgor et al. 
(1985) described the physical depletion technique using an 
elutration centrifuge.)"' The immunomagnetic depletion 
method was first described by Treleaven at el. in 1984. 
3-log depletion of tumor cells from bone marrow was 
obtained in his study."' Since then, many investigators 
reported immunomagnetic depletion (IMD) method using 
cocktail antibodies with various modifications and a result 
of 3-4 log elimination of tumor cells."'-" In Europe and 
America this IMD is applied for clinical medication and 
gives good result. In Japan the IMD is recently performed 
in some institutions."' This paper clarified the IMD method 
using newly produced antibodies and antibodies not pre-
viously used for this technique. Antibodies NCC-LU-243 
and NCC-LU-246 were developed in the NIHON-
KAYAKU Co. Ltd. The reactivity of both antibodies was 
anti-human small cell lung carcinoma. Subclass of immu-
noglobulin of each antibodies was IgG2a in NCC-LU-243 
and IgGI in NCC-LU-246. 5E9 and 3C1 were newly 
produced at the National Children Medical Research Center 
in Tokyo. 5E9 is IgGI class anti human immature teratoma 
antibody. Competion of 5E9 with NKH-1 for binding to 
neuroblastoma cells is due to a reaction of the NCOM on 
the surface of neuroblastoma cells. In contrast the reaction 
of 5E9 is not comletely blocked by NKH-1 so that it is 
clear that 5E9 is not the same antibody as NKH-1. Each
antibodies showed high sensitivity to six neuroblastoma 
cell lines. The optimal dosage of each antibody was deter-
mined with the flow cytometry study." 19.20) In this 
experiment antibodies were used for the cocktail in combi-
nation of four antibodies as previously described. The 
cocktail antibodies gave 1.2-4 times more sensitive to 
tumor surface antigen than a single use. The cocktail 
antibodies showed non-specific reaction with normal bone 
marrow cells. At flow cytometry study percentage of posti-
tive bone marrow cells showed 20.3% on average in cock-
tail antibodies. After two cycle of purging method the ratio 
of recovered vital bone marrow cells/pre-purging cells 
17.1% (23.0% in controlled groups)."' The result by purg-
ing procedure did not differ in recovered bone marrow 
cells from the control group and the purging group. Culture 
assay in soft agar after two cycle purging treatment re-
vealed no toxicity for progenitor hematopoietic ells. 
  Culture assay require sufficient growth capacity of 
tumor cells and is not highly sensitive to detect of residual 
tumor cells after pruging. Dual color immunofluorescence 
staining made it possible to detect less than 2 log residual 
malignant cells.",") The vital fluorescent DNA dye Hoechst 
33342 staining method was first described by Reynolds 
(1985),12) who reported that up to 4-log depletion of resid-
ual cells could be detected with a computerized image 
analyzer and up to 3.3-log with microscopic analysis by 
Hoechst staining. This Hoechst 33342 staining method was 
used in this study for its rapidity and accuracy. 
 Purging procedure using the clinical cell separation unit 
demonstrated a good results of tumor cell elimination and 
bone marrow cell recovery. 
 This newly produced monoclonal antibodies (5E9 and 
3C 1) and two other antibodies (NCC-LU-243 and NCC-
LU-246) had specific reaction for neuroblastoma cells. 
Non-specific reaction of the cocktail antibodies to bone 
marrow cells were recognized, but it was not so significant. 
The cocktail antibodies combined with four antibodies 
(5E9, 3C1, NCC-LU-243 and NCC-LU-246) gave better 
reaction to neurobastoma cells.
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